# Advancing Analytical Method Validation: Lifecycle and Risk-Based Approaches under ICH Q2(R2)

**Jeevan Deshmukh*, Snehal Mane, Vaishnavi Bhadalkar, Anjali Gaddapwar, Vaishnavi Solanke**

Student of Master of Pharmacy in Pharmaceutical Quality Assurance at School of Pharmacy, SRTMU Nanded, 431606.

**Abstract:**
The "international council on harmonisation of technical requirements for registration of pharmaceutical for human use" (ICH) is an initiative that brings together the pharmaceutical industry and regulatory bodies to discuss scientific and technical aspects of the development and registration of pharmaceutical products. The "Q" series quality criteria for harmonisation are part of the ICH guidelines. In order to create a new quality guideline and provide principles pertaining to analytical development procedures, an amendment to the creation of analytical procedures and modifications to the validation of analytical procedures ICH Q2 (R1) are recommended. This review offers a thorough comparison of the revised Q2(R2) guideline and ICH Q2(R1), emphasising significant modifications to validation parameters such specificity, linearity, accuracy, precision, limit of detection (LOD), and quantitation (LOQ). The expanded use of risk assessment tools, system suitability, improved method performance criteria, and the incorporation of Analytical Quality by Design (AQbD) principles are among the recently added components that are also examined in this review. The actual effects of applying Q2(R2) in pharmaceutical laboratories, such as method lifecycle ideas and method performance verification, are also covered in this study. The study seeks to support professionals in implementing a methodical, risk-based approach for method validation that is in line with international regulatory standards through case studies and regulatory insights.

**Key Words:**
ICH guidelines, LOD, LOQ, Analytical Quality by Design (AQbD), Regulatory Standards

**Introduction:**

In the pharmaceutical sector, analytical method validation is essential for guaranteeing the validity, reproducibility, and scientific integrity of analytical techniques used for drug testing.[1] It directly supports patient safety, data integrity, and product quality and is an essential aspect of regulatory compliance. ICH Q2(R1) has been the worldwide standard for validating analytical techniques for almost twenty years, especially those pertaining to drug substance and drug product testing during the stages of research and production. However, as analytical science and pharmaceutical technologies developed, a number of the original Q2(R1) guideline's shortcomings became apparent, including the necessity to closely link validation with method development, a lack of emphasis on lifecycle management, and risk-based thinking.[2]

The International Council for Harmonisation (ICH) published the updated guideline Q2(R2) in 2023 together with a new guideline ICH Q14 on the creation of analytical techniques in order to close these gaps and conform to contemporary quality norms.[3] In addition to maintaining important validation metrics including accuracy, precision, linearity, specificity, and detection limits, the revised Q2(R2) offers a structured framework that facilitates method lifecycle management and promotes interaction with Analytical Quality by Design (AQbD) techniques. As part of regular quality control, the guideline also emphasises the significance of expanded system appropriateness testing, better documentation, and risk assessment tools. The purpose of this paper is to present a thorough comparison of ICH Q2(R1) and Q2(R2), highlight significant developments, and go over how they might be used in pharmaceutical quality assurance. Additionally, it examines how these modifications affect analytical procedures and legal requirements, particularly with regard to worldwide compliance, data dependability, and technique robustness.[4]

Scientific and practical analytical approaches have advanced as a result of the development of analytical tools. Advances in analytical technique development and analytical instrumentation have reduced analysis time and cost while increasing precision and accuracy. The development and validation of analytical methods for active pharmaceutical components, excipients, associated chemicals, drug products, degradation products, residual solvents, etc. is a crucial part of the requirements for regulatory organisations.[5] The official test technique is ultimately the outcome of analytical method development. As a result, quality control labs employed these techniques to verify the drug's efficacy, identification, purity, safety, and performance. Regulatory agencies place a high priority on the importance of analytical processes in production. For a medicinal product to be approved by regulatory bodies, the applicant has to demonstrate control over the entire drug development process through the use of proven analytical techniques.[6]

Topic codes are allocated in accordance with the four categories into which the ICH guidelines are divided: • S: Safety Guidelines • Q: Quality Guidelines • E: Guidelines for Efficacy • M: Guidelines for Multidisciplinary

Guidelines for quality: Important milestones like conducting stability studies, establishing pertinent limits for impurity testing, and adopting a more flexible approach to pharmaceutical quality based on GMP risk management are examples of harmonisation successes in the quality sector. Q1A-Q1F, Q2, Q3A-Q3D, Q4-Q4B, Q5A-Q5E, Q6-Q6B, Q7, Q8, Q9, Q10, Q11, and Q12 are all included. ICH Q2(R1) has been revised, and the guidelines for ICH Q14 are explained[7,8]

**ICH Q2(R1): Principles and Key Concepts**

Developed in 2005, the ICH Q2(R1) guideline offers fundamental guidelines for verifying analytical techniques used in pharmaceutical ingredient and product quality evaluation. Depending on the type of method—identification, assay, impurity testing, or limit testing—it describes particular performance criteria that need to be assessed.[9] The primary goal of method validation is to demonstrate that the method will perform as intended in an accurate, dependable, and consistent manner.[10] Analytical methods have been verified in compliance with Q2 (R1) ICH criteria. The parameters for validation are

- Accuracy
- Precision
- Repeatability
- Intermediate precision

- Reproducibility
- Specificity/Selectivity
- Limit of Detection (LOD)
- Limit of Quantitation (LOQ)
- Linearity
- Range
- Robustness
- Ruggedness
- System suitability testing.

**1.Accuracy-** The degree of agreement between detected values and the available information is referred to as accuracy.[11] It can also be defined as the degree to which the seen value and the true value are similar. It is sometimes referred to as authenticity. The capacity to obtain judgements from at least three concentration levels within the specified range is known as accuracy.[12]

**Determination methods:**

- Application of the analytical method to a known concentration of analyte: To confirm accuracy, apply the analytical method to a known pure analyte (such as a reference standard) and compare the results with validated alternative processes.
- Spiked-placebo recovery method: In this process, a formulation blank that contains all other ingredients but the active is mixed with a known quantity of pure active materials. After that, the mixture is tested and compared to the expected outcomes.
- Standard addition method: This technique entails adding a known quantity of an active element to a sample after it has been assayed. The material is then tested once again. The variations between the two tests are contrasted with anticipated results.
- Recommended Data: According to the ICH document, accuracy should be assessed using at least nine measurements for each of the three concentration levels.
  Acceptance criteria: With the exception of the limit of quantification (LOQ), where it must not exceed 20%, the mean value should be within 15% of the expected value. An accuracy metric is the mean's departure from the nominal value.[13]

**2. Precision:** Sampling should be done several times for a homogeneous sample. Precision is carried out under preset conditions. The degree of agreement between subsequent measurements made from the same homogenous material under comparable circumstances is referred to as an analytical method's precision. Repeatability, intermediate precision, and reproducibility are the three categories of precision that can be taken into consideration.[14]

Expressed as SD/ RSD29 % RSD = Standard Deviation/ Mean x 100[13]

**3. Repeatability:** Repeatability is the accuracy attained in a little amount of time under the same operational conditions, such as when an analyst analyses replicates using the same tools and techniques. Intra-assay precision is another name for repeatability. It needs to be finished in a short amount of time. Nine conclusions are used to evaluate this test. When preparing the sample, it should cover the specified range.[14]

**4. Intermediate precision:** This kind of precision can be achieved by changing the laboratory conditions, having a different person or equipment execute the test on different days, etc. Depending on the planned technique, different levels of intermediate precision are required.[18]

**5. Reproducibility:** This phrase describes the accuracy of two-way research used to standardise techniques for pharmacopoeia procedure addition. An interlaboratory trial is used to evaluate reproducibility.

Acceptance Criteria: Except for the LOQ, which should not exceed 20%, precision at each concentration level should not exceed 15% of the coefficient of variation (CV).

**6. Specificity:** According to ICH, assay specificity is the capacity to accurately quantify an analyte when other substances are present in the sample medium. Certain techniques provide answers for a single analyte. In particular, the ICH paper is divided into three categories.

Identification tests: To confirm an analyte's identity.

Purity tests: To guarantee that every analytical technique carried out permits an accurate declaration of an analyte's impurity content, such as related compounds, heavy metals, etc.

Assay: To produce a precise result that enables a precise assessment of the amount or strength of an analyte in a sample.[13]

**7. Selectivity:** The ability of the technique to identify the analyte when anticipated sample matrix components are present. It simply means that different molecules can be resolved using a separative approach. It calculates two peaks' relative positions. Numerous chemical entities that may or may not be segregated are addressed by this method. Test results for an analyte with and without the inclusion of potentially interfering material are compared to make the determination.

**8. Limit of Detection (LOD):** The lowest amount of analyte in a sample that can be detected but may not always be quantified as an exact number is known as the detection limit of a particular analytical process.

The type of instrument as well as the analysis method will determine the LOD. The basis for measurement is visual assessment. • The response's standard deviation and slope; • The signal to noise ratio.

- **Visual Evaluation:** LOD is established by analysing samples with known analyte concentrations and determining the lowest level at which the analyte may be identified. Both instrumental and non-instrumental procedures can make use of it.
- **Signal to noise ratio:** This method is limited to analytical processes that exhibit baseline noise. It determines the lowest concentration at which the analyte may be identified by comparing measured signals from samples with known low analyte concentrations with those of blank samples. It is commonly agreed that the signal to noise ratio should be 2:1 or 3:1.
- **The standard deviation of the response and the slope:** LOD = 3.3σ/S σ = Standard deviation of the response. S = Slope of the calibration curve of the analyte from regression line.[14]

**9. Limit of Quantification:** The lowest concentration of analyte in a sample that can be accurately and precisely quantified. In quantitative assays, the quantitation limit is a parameter used to identify low concentrations of compounds, such as pollutants and

degradation products, in sample matrices. Depending on whether the process is instrumental or non-instrumental, there are various methods for determining the quantitation limit. Alternative strategies to the ones listed below might be appropriate.

- **Visual Evaluation:** LOD is established by analysing samples with known analyte concentrations and determining the lowest level at which the analyte may be identified. Both instrumental and non-instrumental procedures can make use of it.
- **Signal-to-Noise Approach:** This method is limited to analytical processes that exhibit baseline noise. It determines the lowest concentration at which the analyte may be identified by comparing measured signals from samples with known low analyte concentrations with those of blank samples. It is generally agreed that the signal to noise ratio is 10:1.
- **The standard deviation of the response and the slope –** LOD = 10 σ/**S** σ = Standard deviation of the response. S = Slope of the calibration curve of the analyte from regression line.[15]

**10. Linearity:** The calibration curve, which is commonly used to illustrate linearity, shows that the quantity of the testing chemical in the sample is directly proportionate to the measurement or data obtained from the material's testing. We refer to this ability as linearity. It must to be completed within range. The linearity examines the value of R2. It needs to be close to one, or within the range. Samples are made by either weighing various sample volumes in accordance with protocol or diluting a standard stock solution. Prepare at different concentrations of solutions. It is necessary to prepare at least five concentrations for analysis. (ICH Harmonised Tripartite Guidelines, 2005).

**11.Range:** The interval between the highest and lowest analyte concentrations (amounts) in the sample (containing these concentrations) for which it has been shown that the analytical technique has an appropriate degree of precision, accuracy, and linearity is known as the analytical procedure's range.

The minimum defined ranges listed below must to be taken into into consideration:

- 80–120% of the test concentration is used in the assay of a drug substance or a completed drug product.
- 70–130% of the test concentration is the content homogeneity.
- Dissolution testing: within the given range +/-20%. 120% of the impurity specification limit is the impurity reporting threshold.[16]

**12. Robustness:** An analytical method's robustness is determined by how well it can withstand minor, intentional adjustments to its parameters. The variable method parameters in HPLC technique may involves flow rate, column temperature, sample temperature, pH and mobile phase composition.[14]

**13. Ruggedness-** The reproducibility of test results among labs and analysts, accounting for potential environmental changes, is referred to as robustness. The consistency of test results obtained from the same samples under varied conditions, such as different laboratories, analysts, instruments, reagents, temperature, and time, is referred to as the robustness of an analytical process.[15]

**14. System Suitability Testing:** This guarantees that a method operates within the approved boundaries after it has been validated. The tests take into account the apparatus, electronics, analytical procedures, and samples to be examined as a cohesive system that can be assessed as such.[17]

**Limitations and Need for Revision in ICH Q2(R1) :**

The most modern applications of analytical techniques, such as Raman or Near Infrared (NIR) spectroscopy, are not covered in the current Q2 (R1) "Guide to Verifying Analysis Procedures: Text and Method." The release of inadequate verification data for these analytical procedures may result from a lack of advice on these analytical data sets. This has caused duplicate information requests and responses, which may postpone the clearance of applications. The primary cause of this is multivariate model-based processes, which lack an ICH verification guide. NIR and Raman spectroscopy tools are frequently employed in process control and real-time pharmaceutical product testing employing a variety of analytical techniques. The existing Q2 (R1) technique is insufficient to determine the applicability of multivariate methods given the distinctions between them and traditional methods. For instance, each test verifies and validates the efficacy of conventional approaches that employ indexing, analysis, and anonymous samples. On the other hand, the reference standards are typically not applied throughout the analysis in model-based techniques of different models. Because of this, robust system creation, validation, and upkeep are crucial for accurate forecasts throughout life.[19]

**Understanding the Updated ICH Q2(R2) Framework:**

The regulatory framework for analytical method validation underwent a major development with the release of ICH Q2(R2) in March 2023. This revised guideline, which was created in accordance with ICH Q14 on Analytical Procedure Development, shows a move towards a more comprehensive, risk- and science-based approach to method validation. Q2(R2) emphasises the full method lifetime, from development to routine use and performance monitoring, in contrast to Q2(R1), which concentrated only on the validation stage. This promotes better integration between method development, validation, and continuous improvement and is consistent with the more general pharmaceutical quality system concepts outlined in ICH Q8 to Q12. Important improvements in Q2 (R2) consist of:

- Lifecycle-Based Validation: Promotes continual evaluation of method performance after the initial validation stage.
- Integration with Risk Management: Proactively identifying and controlling method-related risks through the use of tools like FMEA and Ishikawa diagrams.
- System Suitability Testing (SST): This is now clearly advised as a regular and essential component of method validation.
- Enhanced Flexibility and Clarity: More information is given on how to apply metrics like robustness, accuracy, and specificity across a range of analytical methodologies, including platform-based and contemporary approaches.
- Support for AQbD: By allowing the use of AQbD concepts like developing an Analytical Target Profile (ATP) and investigating Method Operable Design Regions (MODR), Q2(R2) enhances Q14.[3]

Furthermore, Q2(R2) provides improved assistance on complicated situations, including the determination of acceptance criteria, the use of surrogate standards, and bracketing techniques for validation batches. These enhancements contribute to ensuring that analytical techniques are both appropriate for their intended use and flexible enough to accommodate changing requirements throughout the course of a product's lifecycle. The updated guide will provide clarification on typical process validation features, including nuclear magnetic resonance spectroscopy (NMR), NIR, and hyphenated techniques, such as CE-MS, CE-ICP-MS, LC-NMR, GC-MS, and LC-MS. The data generated is reliable in terms of frequency range or weight to charge the average distance, despite the fact that these

approaches employ quite diverse equipment. If required, data analysis can be made easier by using multivariate statistical analysis appropriately to compare test and reference samples.[4]
The following procedures that depend on multivariate approaches will also be covered: The definition of validation characteristics that apply to multivariate methods may vary depending on the application area (e.g., dosage form assay vs. blending monitoring, batch vs. continuous process, identification vs. quantification). - Robustness, which is well understood but lacks a quantitative measure; - Important technique characteristics, such as the number of latent variables, developed during method development.[20]

**Comparative Analysis: ICH Q2(R1) VS Q2(R2)**

The purposeful change in regulatory thinking from a validation checklist to a scientific, lifecycle-based approach for guaranteeing method performance is reflected in the change from ICH Q2(R1) to Q2(R2). The revised guideline offers broader definitions, more flexibility, and a more robust connection with risk management and AQbD concepts, even if many fundamental validation requirements are still the same. All things considered, Q2(R2) expands the scope of Q2(R1) to include contemporary analytical tools, promotes proactive quality assurance, and supports ongoing method control throughout a product's lifecycle. This improvement is especially helpful in regulatory settings where technique dependability and data integrity are being scrutinised more and more.[3]

**Table No 1: Summarizes the key differences between the two versions**

| Parameter ICH Q2(R1) | ICH Q2(R1) | ICH Q2(R2) | Key Differences |
|---|---|---|---|
| Linearity, Range, Accuracy, Precision | Required | Required | Same parameters, but with broader application to modern techniques. |
| Robustness | Optional, limited detail | Recommended | Lifecycle-focused; integrated with development and verification.[22] |
| Lifecycle Approach | Absent | Central concept | Promotes continuous method performance verification. |
| Specificity | Required | Required | More guidance on matrix effects and peak purity.[21] |
| Risk Assessment | Not addressed | Required | Encouraged to justify design and control strategies |
| System Suitability | Implied | Emphasized | Now explicitly linked to method performance monitoring.[8] |
| AQbD Integration | Not addressed | Supported | Alignment with Q14 to define ATP and MODR for analytical procedures[7] |
| LOD & LOQ | Required for limit tests | Required | Clearer guidance on estimation approaches and reporting.[7] |

**Statistical Tools in the Transition from Q2(R1) to Q2(R2):**

ICH Q2(R1) mainly offered a generic framework for validation, mentioning statistical analysis in relation to common computations such as:

- Calculate the detection limit (DL = 3.3sigma / S) and quantitation limit (QL = 10sigma / S) using the calibration curve's slope (S) and standard deviation (\sigma \)).
- Using linear regression to get the correlation coefficient, y-intercept, slope, and residual sum of squares for linearity assessments.
- Using standard deviation or relative standard deviation (% RSD) to express precision (repeatability and intermediate precision). Recovery studies are validated statistically for accuracy.

**Structured Framework for Analytical Method Lifecycle:**




**Figure No. 1[23]**

**Regulatory Frameworks in a Global Context:**

The adoption of ICH Q2(R2) has caused regulatory bodies all around the world to reassess existing standards for lifecycle management and analytical technique validation. Risk-based, science-driven validation procedures that go beyond static testing and prioritise continuous method control are being promoted more and more by international agencies like the U.S. FDA, EMA, MHRA, and CDSCO.[23] As seen by its 2015 advice promoting the integration of method development with performance qualification and system suitability18, the U.S. FDA has long supported the principles currently included in Q2(R2). Pharmaceutical makers are now required by the agency to show that a technique will continue to function throughout the product lifespan in addition to its initial effectiveness.[24] Similar views have been expressed in the European Union by the EMA, which has promoted lifecycle-based validation by adopting ICH Q8 Q12 and more recently Q2(R2) and Q14.[25] Method robustness, data integrity, and the requirement for sufficient ongoing verification systems—particularly in biologics and generics—are highlighted in EMA's guidelines.[26] The CDSCO in India is becoming more in line with ICH standards, especially after being acknowledged as an ICH member. In accordance with international standards, Indian pharmaceutical businesses are now expected to abandon check-box validation procedures and adopt risk-based, lifecycle approaches.[27] Furthermore, issues pertaining to insufficient change control documentation, lack of performance verification, and missing method robustness data have been the focus of regulatory inspections throughout markets. This change reflects a broader expectation that method validation should be seen as a dynamic, quality-driven process that changes with product knowledge and analytical improvements rather than as a one-time event.[28]

**Practical Evaluation Through Case Studies:**

Several pharmaceutical companies have proactively implemented lifecycle-based method validation methods, demonstrating the practical implementation of ICH Q2(R2) ideas. The advantages of combining method development with validation and continuous performance monitoring are demonstrated by these practical applications.[29] In one instance, the Analytical Target Profile (ATP) technique was used to define performance objectives from the outset by a multinational corporation creating an HPLC method for impurity profiling in a generic medicine. The technique variables most likely to impact accuracy and precision were identified using risk assessment methods like FMEA (Failure Mode and Effects Analysis). Consequently, a reliable approach was created within a specified way Method Operable Design Region (MODR) decreasing the possibility of method failure when using it frequently A biologics company validated a capillary electrophoresis (CE) approach for charge variation analysis in another instance.[30] To guarantee ongoing method control, the team employed a system suitability test (SST) technique and carried out robustness testing during early development. Following regulatory inspection, the company stated that incorporating lifecycle concepts prevented them from having to revalidate when they made small adjustments to equipment or sample preparation procedures. Adopting the new principles greatly improved documentation procedures, decreased batch release delays, and increased audit readiness, according to a recent pilot study on integrating Q2(R2) in analytical labs of a formulation plant in Indian business. According to analysts, lifecycle-based procedures improved the structure and scientific validity of enquiries into out-of-specification (OOS) results.[31]

These illustrations highlight the importance of ICH Q2(R2) in enhancing data integrity, regulatory compliance, and method robustness.[32] Early adopters demonstrate that the long-term improvements in dependability and regulatory confidence surpass the initial efforts, despite practical hurdles including training, documentation revisions, and integration with current quality systems[33]

**Existing Barriers and Upcoming Opportunities:**

Implementing ICH Q2(R2) throughout the pharmaceutical business is not without difficulties, despite the fact that it offers substantial advantages for regulatory compliance and analytical dependability. To completely adopt a lifecycle-based approach, many organizations—particularly those in the generics industry and small-to-mid-scale operations—face operational, practical, and knowledge-based obstacles. The absence of formal training and knowledge among QA staff and analytical scientists is one of the main issues.[34] In addition to procedural changes, the shift from traditional validation approaches to a more adaptable, risk-based framework necessitates a culture change in the way method development and verification are conducted. Terms like ATP, MODR, and performance verification are still poorly understood or implemented inconsistently in the absence of this foundation. The complexity of the paperwork is another challenge. Lifecycle validation necessitates ongoing data creation, trending, and risk assessment documentation, which could be too much for teams without strong LIMS systems or contemporary digital technologies.[35]

Furthermore, there are technological challenges in incorporating Q2(R2) concepts into legacy methods, particularly when those methods lack original development history or robustness data28. Additionally, organisations must review their change control, SOPs, and CAPA systems in order to comply with regulators' demands for proof of continuous method control.[36] Investing in cross-functional cooperation across R&D, QA, QC, and regulatory affairs is necessary to close this gap in addition to training. Predictive analytics, real-time performance monitoring, and machine learning techniques will probably define analytical method validation in the future. The analytical lifecycle model described in ICH Q2(R2) may become the norm for guaranteeing method robustness in both conventional pharmaceutical therapies as digital transformation picks up speed.[37]

**Conclusion:**

Analytical technique validation has advanced significantly with the transformation of ICH Q2(R1) to Q2(R2). The new guideline provides a more solid, adaptable, and scientifically sound framework for method development and control by supporting a lifecycle-based approach, incorporating risk management, and fostering alignment with analytical quality by design (AQbD). The incorporation of contemporary ideas like continuous improvement, system appropriateness, and performance verification reflects the changing demands of international regulatory bodies. The long-term advantages in terms of data integrity, compliance, and method reliability are substantial, even though implementation challenges still exist, particularly with regard to training, documentation, and interaction with current systems.

This review article describes what validation is, how it works, why it's important, and details every validation metric, including linearity, accuracy, precision, range, LOD, LOQ, specificity, etc. In the pharmaceutical industry, validation is an essential tool that ensures quality is incorporated into the process that supports drug development and production. This review article's primary goal is to raise the standard of analytical technique development and validation.

**References:**


1. ICH. Validation of Analytical Procedures: Text and Methodology Q2(R1). International Council for Harmonisation; 2005.
2. Ferenczi-Fodor K, Renger B, Végh Z. Validation and verification of analytical methods in the pharmaceutical industry. J Chromatogr Sci. 2010;48(4):318–26.
3. ICH. Guideline Q2(R2) on Validation of Analytical Procedures. International Council for Harmonisation; 2023 Mar.
4. ICH. Guideline Q14 on Analytical Procedure Development. International Council for Harmonisation; 2023 Mar.
5. Mali, Chetan, Bharati Sonawane, and Rohit Mali. 2025. "Recent Advances in Analytical Method Validation as per ICH Q2(R2): A Comparative Review with ICH Q2(R1)." International Journal of Pharmaceutical Sciences 3 (7): 1560–1567. https://doi.org/10.5281/zenodo.15863307..
6. Nikam, Kiran V., Sandhya Shinde (Kadam), and Vivekkumar K. Redasani. 2024. "A Review on Analytical Method Development and Validation (With Case Study)." International Journal of Pharmaceutical Research and Applications 9 (3): 1305–1318. https://doi.org/10.35629/4494-090313051318..
7. Chaursiya, Ajay C., and Rajesh L. Dumpala. 2020. "A Review on Revision of ICH Q2 (R1) and New ICH Q14 Guidance." Global Journal for Pharma and Allied Sciences 1 (6): 1–6. https://doi.org/10.47583/gjfpas.2020.v01i06.001..
8. Koneru PK, Sahu R, Kumar A. Analytical Quality by Design (AQbD): A tool for regulatory flexibility and robust method development. Pharm Regul Aff. 2021;10(2):1–5.
9. Rajesh Dumpala, Chirag Patil An Overview of Regulatory Affairs in Pharmaceutical Industry, International Journal of Universal Pharmacy and Bio Sciences, 2017; 9(4):18-24.
10. Gandhi A, Roy C; Quality by design (QbD) in pharmaceutical industry: tools, perspectives and challenges; pharmatutor; 2016;4(11):12-20.
11. https://www.ich.org/page/ich-guidelines
12. Srivastava RK, Kumar SS. An updated review: analytical method validation. Eur J Pharm Med Res 2017; 4:774-84
13. Sushila Dagadu Chavan, and Deepa Mahendra Desai . Analytical methodvalidation: A brief review. 16(02), 389– 402
14. Panchumarthy Ravisankar, Ch. Naga Navya1, D. Pravallika1, D. Navya Sri1.A Review on Step by Step Analytical method validation. (e)-ISSN:2250- 3013,(p)-ISSN:2319-4219
15. B.K. Sharma, Instrumental method of chemical analysis (29th Ed., Meerut, Chromatography, HPLC, Goel Publishing House, 2013) 286-385.
16. G. Lavanya, M. Sunil, M.M. Eswarudu, M. Chinna Eswaraiah, K. Harisudha and B. Naga Spandana. ANALYTICAL METHOD VALIDATION: AN UPDATED REVIEW. ISSN: 0975-8232, Lavanya et al., IJPSR, 2013; Vol. 4(4): 1280-1286
17. Tijare LK, Rangari NT, Mahajan UN. A review on bioanalytical method development and validation. Asian J Pharm Clin Res 2016; 9:6-10.
18. Neera Chikanbanjar, Nidhi Semwal, UreenaJyakhwa. A Review on Analytical Method Validation. Volume 1 Issue 1, CR Journals (Page no.48-58)2020

19. Ferenczi-Fodor K, Renger B, Végh Z. Validation and verification of analytical methods in the pharmaceutical industry. J Chromatogr Sci. 2010;48(4):318–26.
20. EMA. ICH Q2(R2) validation of analytical procedures: scientific guideline. European Medicines Agency; 2024 Jun. Available from: https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
21. FDA. Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. U.S. Food and Drug Administration; 2015.
22. Fekete S, Guillarme D. Lifecycle management of analytical procedures: current status and future trends. TrAC Trends Anal Chem. 2020; 132:116045
23. Analytical Method Lifecycle Management in Pharmaceutical Industry: a Review | AAPS Pharm SciTech https://share.google/MQWrzxEwgqyVqdTGZ
24. Maurer R, Tsai J. Global regulatory perspectives on analytical method lifecycle and quality risk management. Pharm Outsourcing. 2023;24(1):18–23.
25. U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry. Silver Spring (MD): FDA; 2015.
26. European Medicines Agency. Guideline on the use of quality risk management in pharmaceutical development. EMA/CHMP/ICH/149595/2022; 2023.
27. Sharma R, Kulkarni A. India's evolving regulatory landscape for analytical method validation. Indian Pharm. 2023;22(9):25–30.
28. Martinez L, Walker B. Key trends in regulatory inspections: Method validation findings in 2022–2023. Pharm Qual Europe. 2023;17(4):10–15.
29. Rao GV, Bansal M. Implementation of analytical target profile in HPLC method development under ICH Q2(R2). J Pharm Sci Technol. 2023;77(5):215–21.
30. Kumar A, Sequeira J. Lifecycle management of CE methods in biopharmaceutical analysis: Regulatory insights. BioProcess Int. 2022;20(3):36–42.
31. Joshi P, Mehta R. Application of ICH Q2(R2) principles in Indian pharmaceutical QC labs: A case study. Int J Pharm Qual Assur. 2023;14(2):88–94.
32. Tan B, Lee C. Real-world experiences implementing analytical lifecycle strategies: Lessons from industry. Pharm Eng. 2022;42(6):20–26.
33. Menon A, Pillai R. Bridging the skill gap in lifecycle-based method validation: An industry survey. J Pharm Educ Res. 2022;13(3):110–16.
34. Zhang H, Chen Y. Leveraging LIMS for method lifecycle management under ICH Q2(R2). Pharm Technol Asia. 2023;15(1):27–32.
35. Patel D, Shah K. Challenges in retrofitting legacy methods to meet Q2(R2) requirements. Int J Pharm Chem Anal. 2023;10(2):45–50.
36. Montoya L, Singh A. Evolving role of QA in analytical lifecycle oversight. Pharm Qual Manage Rev. 2023;9(4):12–18.
37. Jadhav S, Srivastava A. Future of method validation: AI and real-time analytics in pharmaceutical QA. Drug Dev Ind Pharm. 2023;49(6):900–08